loader
Please Wait
Applying Filters...

Seqens Seqens

X

Approved Drug Products containing 201292 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 BOEHRINGER INGELHEIM (3)

filter

01 TABLET;ORAL (3)

filter

01 RX (3)

filter

01 GILOTRIF (3)

filter

01 Yes (3)

URL Supplier Web Content
TABLET; ORAL
EQ 20MG BASE
2013-07-12
201292
GILOTRIF
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
TABLET; ORAL
EQ 30MG BASE
2013-07-12
201292
GILOTRIF
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
TABLET; ORAL
EQ 40MG BASE
2013-07-12
201292
GILOTRIF
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for FDA Orange Book APPLICATION 201292

Looking for FDA Orange Book APPLICATION 201292 3

19

Boehringer Ingelheim GmbH, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is AFATINIB DIMALEATE, with a corresponding application number 201292.

Regulatory Information RX

With a dosage strength EQ 20MG BASE

Dosage Form Route TABLET; ORAL

Reference Listed Drug Yes

Approved since 2013-07-12

18

Boehringer Ingelheim GmbH, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is AFATINIB DIMALEATE, with a corresponding application number 201292.

Regulatory Information RX

With a dosage strength EQ 30MG BASE

Dosage Form Route TABLET; ORAL

Reference Listed Drug Yes

Approved since 2013-07-12

17

Boehringer Ingelheim GmbH, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is AFATINIB DIMALEATE, with a corresponding application number 201292.

Regulatory Information RX

With a dosage strength EQ 40MG BASE

Dosage Form Route TABLET; ORAL

Reference Listed Drug Yes

Approved since 2013-07-12

Post Enquiry
POST ENQUIRY